Juglone Inhibits Proliferation of HPV-Positive Cervical Cancer Cells Specifically

Area of Science:

• Oncology
• Virology
• Pharmacology

Background:

• Human papillomaviruses (HPVs), notably HPV 16 and 18, are strongly linked to cervical cancer development.
• Targeting HPV-positive cervical cancer is crucial for effective treatment strategies.
• Juglone, derived from walnut, exhibits potential antineoplastic properties.

Purpose of the Study:

• To investigate the molecular mechanisms underlying juglone's antineoplastic effects on HPV-positive cervical cancer cells.
• To determine juglone's impact on cell proliferation, apoptosis, and cell cycle progression in HPV-positive cervical cancer.

Main Methods:

• Cell culture of HPV-positive cervical cancer cells treated with varying concentrations of juglone.
• Assessment of cell proliferation, apoptosis, and cell cycle distribution.
• Western blot analysis to examine the expression of key proteins, including the Bcl-2 family and caspases.
• siRNA-mediated knockdown of Pin1 to evaluate its role in juglone's efficacy.

Main Results:

• Juglone demonstrated dose-dependent inhibition of HPV-positive cervical cancer cell growth.
• Knockdown of Pin1 significantly reduced the antiproliferative effect of juglone.
• Juglone induced apoptosis and altered cell cycle progression in HPV-positive cells.
• Western blot analysis revealed that juglone modulates the Bcl-2 family, activating caspase-dependent apoptosis.

Conclusions:

• Juglone exerts its anti-cancer effects by inhibiting proliferation and inducing apoptosis in HPV-positive cervical cancer cells.
• The mechanism involves the modulation of the Bcl-2 family and activation of caspase-dependent pathways, potentially mediated by Pin1.
• Juglone represents a promising therapeutic agent for HPV-positive cervical cancer, warranting further investigation for clinical application.